Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass

Henry G. Bone, Michael A. Bolognese, Chui Kin Yuen, David L. Kendler, Paul D. Miller, Yu Ching Yang, Luanda Grazette, Javier San Martin, John Christopher G. Gallagher

Research output: Contribution to journalArticle

231 Citations (Scopus)

Abstract

Context: Denosumab treatment for 24 months increased bone mineral density (BMD) and reduced bone turnover markers (BTM) in postmenopausal women. Objective: The aim was to determine the effects of prior denosumab or placebo injections on BMD, BTM, and safety over 24 months after treatment discontinuation. Design: We conducted an off-treatment extension of a phase 3, randomized, double-blind, parallel- group study. Participants: A total of 256 postmenopausal women with a mean age of 59 yr and a mean lumbar spine T-score of ≤1.61 at randomization participated in the study. Interventions: Participants received placebo or 60 mg denosumab every 6 months for 24 months, followed by 24 months off treatment. Main Outcome Measures: We measured the percentage changes in BMD and BTM, and evaluated safety. Results: Of the 256 participants enrolled in the posttreatment phase, 87% completed the study. During 24 months of denosumab treatment, BMD increased (lumbar spine, 6.4%; total hip, 3.6%; 1/3 radius, 1.4%), and BTM decreased (serum C-terminal telopeptide of type 1 collagen, 63%; and N-terminal propeptide of type 1 procollagen, 47%),comparedwith placebo. After discontinuation, BMD declined, but the previously treated denosumab group maintained higher BMD than the previously treated placebo group at these sites (P= 0.05). Final BMD at month 48 strongly correlated with month 0 BMD. After denosumab discontinuation, BTM increased above baseline within 3 months (serum C-terminal telopeptide of type 1 collagen) or 6 months (N-terminal propeptide of type 1 procollagen) and returned to baseline by month 48. Adverse event rates during the off-treatment phase were similar between groups. Conclusions: In postmenopausalwomenwith lowBMD,the effects of 60mgdenosumabtreatment for 24 months on BMD and BTM are reversible upon discontinuation, reflecting its biological mechanism of action. Residual BMD measurements remained above those of the group previously treated with placebo.

Original languageEnglish
Pages (from-to)972-980
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume96
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

Bone Remodeling
Bone Density
Minerals
Bone
Bone and Bones
Collagen Type I
Placebos
Therapeutics
Spine
Denosumab
Safety
Random Allocation
Hip
Biomarkers
Outcome Assessment (Health Care)
Injections

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. / Bone, Henry G.; Bolognese, Michael A.; Yuen, Chui Kin; Kendler, David L.; Miller, Paul D.; Yang, Yu Ching; Grazette, Luanda; Martin, Javier San; Gallagher, John Christopher G.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 96, No. 4, 04.2011, p. 972-980.

Research output: Contribution to journalArticle

Bone, Henry G. ; Bolognese, Michael A. ; Yuen, Chui Kin ; Kendler, David L. ; Miller, Paul D. ; Yang, Yu Ching ; Grazette, Luanda ; Martin, Javier San ; Gallagher, John Christopher G. / Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. In: Journal of Clinical Endocrinology and Metabolism. 2011 ; Vol. 96, No. 4. pp. 972-980.
@article{5ff77ccf52074877838831e0d0900262,
title = "Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass",
abstract = "Context: Denosumab treatment for 24 months increased bone mineral density (BMD) and reduced bone turnover markers (BTM) in postmenopausal women. Objective: The aim was to determine the effects of prior denosumab or placebo injections on BMD, BTM, and safety over 24 months after treatment discontinuation. Design: We conducted an off-treatment extension of a phase 3, randomized, double-blind, parallel- group study. Participants: A total of 256 postmenopausal women with a mean age of 59 yr and a mean lumbar spine T-score of ≤1.61 at randomization participated in the study. Interventions: Participants received placebo or 60 mg denosumab every 6 months for 24 months, followed by 24 months off treatment. Main Outcome Measures: We measured the percentage changes in BMD and BTM, and evaluated safety. Results: Of the 256 participants enrolled in the posttreatment phase, 87{\%} completed the study. During 24 months of denosumab treatment, BMD increased (lumbar spine, 6.4{\%}; total hip, 3.6{\%}; 1/3 radius, 1.4{\%}), and BTM decreased (serum C-terminal telopeptide of type 1 collagen, 63{\%}; and N-terminal propeptide of type 1 procollagen, 47{\%}),comparedwith placebo. After discontinuation, BMD declined, but the previously treated denosumab group maintained higher BMD than the previously treated placebo group at these sites (P= 0.05). Final BMD at month 48 strongly correlated with month 0 BMD. After denosumab discontinuation, BTM increased above baseline within 3 months (serum C-terminal telopeptide of type 1 collagen) or 6 months (N-terminal propeptide of type 1 procollagen) and returned to baseline by month 48. Adverse event rates during the off-treatment phase were similar between groups. Conclusions: In postmenopausalwomenwith lowBMD,the effects of 60mgdenosumabtreatment for 24 months on BMD and BTM are reversible upon discontinuation, reflecting its biological mechanism of action. Residual BMD measurements remained above those of the group previously treated with placebo.",
author = "Bone, {Henry G.} and Bolognese, {Michael A.} and Yuen, {Chui Kin} and Kendler, {David L.} and Miller, {Paul D.} and Yang, {Yu Ching} and Luanda Grazette and Martin, {Javier San} and Gallagher, {John Christopher G.}",
year = "2011",
month = "4",
doi = "10.1210/jc.2010-1502",
language = "English",
volume = "96",
pages = "972--980",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass

AU - Bone, Henry G.

AU - Bolognese, Michael A.

AU - Yuen, Chui Kin

AU - Kendler, David L.

AU - Miller, Paul D.

AU - Yang, Yu Ching

AU - Grazette, Luanda

AU - Martin, Javier San

AU - Gallagher, John Christopher G.

PY - 2011/4

Y1 - 2011/4

N2 - Context: Denosumab treatment for 24 months increased bone mineral density (BMD) and reduced bone turnover markers (BTM) in postmenopausal women. Objective: The aim was to determine the effects of prior denosumab or placebo injections on BMD, BTM, and safety over 24 months after treatment discontinuation. Design: We conducted an off-treatment extension of a phase 3, randomized, double-blind, parallel- group study. Participants: A total of 256 postmenopausal women with a mean age of 59 yr and a mean lumbar spine T-score of ≤1.61 at randomization participated in the study. Interventions: Participants received placebo or 60 mg denosumab every 6 months for 24 months, followed by 24 months off treatment. Main Outcome Measures: We measured the percentage changes in BMD and BTM, and evaluated safety. Results: Of the 256 participants enrolled in the posttreatment phase, 87% completed the study. During 24 months of denosumab treatment, BMD increased (lumbar spine, 6.4%; total hip, 3.6%; 1/3 radius, 1.4%), and BTM decreased (serum C-terminal telopeptide of type 1 collagen, 63%; and N-terminal propeptide of type 1 procollagen, 47%),comparedwith placebo. After discontinuation, BMD declined, but the previously treated denosumab group maintained higher BMD than the previously treated placebo group at these sites (P= 0.05). Final BMD at month 48 strongly correlated with month 0 BMD. After denosumab discontinuation, BTM increased above baseline within 3 months (serum C-terminal telopeptide of type 1 collagen) or 6 months (N-terminal propeptide of type 1 procollagen) and returned to baseline by month 48. Adverse event rates during the off-treatment phase were similar between groups. Conclusions: In postmenopausalwomenwith lowBMD,the effects of 60mgdenosumabtreatment for 24 months on BMD and BTM are reversible upon discontinuation, reflecting its biological mechanism of action. Residual BMD measurements remained above those of the group previously treated with placebo.

AB - Context: Denosumab treatment for 24 months increased bone mineral density (BMD) and reduced bone turnover markers (BTM) in postmenopausal women. Objective: The aim was to determine the effects of prior denosumab or placebo injections on BMD, BTM, and safety over 24 months after treatment discontinuation. Design: We conducted an off-treatment extension of a phase 3, randomized, double-blind, parallel- group study. Participants: A total of 256 postmenopausal women with a mean age of 59 yr and a mean lumbar spine T-score of ≤1.61 at randomization participated in the study. Interventions: Participants received placebo or 60 mg denosumab every 6 months for 24 months, followed by 24 months off treatment. Main Outcome Measures: We measured the percentage changes in BMD and BTM, and evaluated safety. Results: Of the 256 participants enrolled in the posttreatment phase, 87% completed the study. During 24 months of denosumab treatment, BMD increased (lumbar spine, 6.4%; total hip, 3.6%; 1/3 radius, 1.4%), and BTM decreased (serum C-terminal telopeptide of type 1 collagen, 63%; and N-terminal propeptide of type 1 procollagen, 47%),comparedwith placebo. After discontinuation, BMD declined, but the previously treated denosumab group maintained higher BMD than the previously treated placebo group at these sites (P= 0.05). Final BMD at month 48 strongly correlated with month 0 BMD. After denosumab discontinuation, BTM increased above baseline within 3 months (serum C-terminal telopeptide of type 1 collagen) or 6 months (N-terminal propeptide of type 1 procollagen) and returned to baseline by month 48. Adverse event rates during the off-treatment phase were similar between groups. Conclusions: In postmenopausalwomenwith lowBMD,the effects of 60mgdenosumabtreatment for 24 months on BMD and BTM are reversible upon discontinuation, reflecting its biological mechanism of action. Residual BMD measurements remained above those of the group previously treated with placebo.

UR - http://www.scopus.com/inward/record.url?scp=79953897155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953897155&partnerID=8YFLogxK

U2 - 10.1210/jc.2010-1502

DO - 10.1210/jc.2010-1502

M3 - Article

C2 - 21289258

AN - SCOPUS:79953897155

VL - 96

SP - 972

EP - 980

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -